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 INTRODUCTION 
 A major factor contributing to the continued public health 
burden of malaria is the spread of drug-resistant  Plasmodium 
parasites. 1, 2 In response to the threat posed by antimalarial 
drug resistance the World Health Organization (WHO) has 
recommended a shift from antimalarial monotherapy, par-
ticularly chloroquine (CQ) and sulfadoxine-pyrimethamine 
(SP) to combination therapy. 3 It is expected that combining 
antimalarials with differing modes of action would reduce the 
probability of a resistant (mutant) parasite surviving treat-
ment. 4 Artemisinin-based combination therapies (ACTs) are 
preferred to other combination therapies or monotherapies, 
as they have higher cure rates, more rapid parasite clearance 
times, and the potential to reduce malaria transmission caused 
by their gametocidal effect, further limiting the spread of anti-
malarial resistance. 5– 7 
 By 2008, 77 countries had adopted an ACT as their first line 
antimalarial treatment policy. 8 Artesunate plus SP (AS-SP), 
one of the WHO recommended ACTs, 7 has the operational 
advantages of lower cost and the full dose of the partner drug 
being administered as a single dose, but unfortunately is not 
suitable for manufacture as a fixed dose combination. Separate 
tablets, even if blister packed, allow patients to choose which 
drug to take, potentially negating the purported benefits of 
combination therapy. The widespread use of SP monotherapy 
has resulted in a high prevalence of SP-resistant  Plasmodium 
falciparum isolates in many southern African countries. 9– 13 
There may be further selection for these resistant parasites 
through the current large-scale use of SP-monotherapy for 
intermittent preventive treatment (IPT) of high-risk groups, 
particularly pregnant women. 14 
 Resistance to SP develops because of an accumulation of sin-
gle nucleotide polymorphisms in the dihydrofolate reductase 
( dhfr ) and dihydropteroate synthetase ( dhps ) genes. The pres-
ence of three mutations in the  dhfr gene (at codons 51, 59, 
and 108, known as the  dhfr triple) and two mutations in the 
 dhps gene (at codons 437 and 540, known as the  dhps double), 
together referred to as the “quintuple mutation,” is strongly 
associated with  in vivo and  in vitro SP resistance in East and 
Southern Africa. 10, 11 
 Within the case management component of the Lubombo 
Spatial Development Initiative malaria control program, 15 
large-scale deployment of AS-SP as first line treatment of 
definitely diagnosed uncomplicated malaria commenced in 
Maputo Province, southern Mozambique, in 2004. This ACT 
was selected to replace chloroquine following  in vivo efficacy 
trials, conducted from 2003 until 2005, which showed AS-SP to 
be highly effective with an adequate clinical and parasitological 
response of 98% at 42 days. 16 This study, conducted on uncom-
plicated malaria patients 1 to 65 years of age, found an over 
3-fold increased risk of recrudescence among patients infected 
with parasites carrying the “quintuple” mutation. Phased imple-
mentation began in the Namaacha District in April 2004 and 
included all districts in Maputo Province by May 2006 ( Figure 1 ). 
Adequate supplies of AS-SP have been sustained in all pub-
lic sector facilities since implementation of this policy, with 
ACT availability extended to the community health post level 
in 2006. This has ensured high ACT coverage following the 
deployment of this treatment policy. 17 
 Limiting the spread of antimalarial resistance is one of the 
key rationales motivating ACT deployment. However, sur-
prisingly little research has been conducted on the spread of 
antimalarial resistance following large-scale ACT deployment, 
with almost all the research in this area being conducted in 
Asia. 18, 19 Antimalarial resistance is usually monitored through 
 in vivo therapeutic efficacy studies, which are costly and may 
not be the most sensitive tool for detecting resistance given 
the contribution of partial immunity to clinical and parasi-
tological treatment response. 20 With highly effective malaria 
control programs, the marked reductions in malaria inci-
dence decrease the feasibility of conducting adequately pow-
ered  in vivo therapeutic efficacy studies. This study reports on 
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the large-scale surveillance of  dhfr and  dhps mutations over 
a 5-year period before and after the wide-scale deployment 
of AS-SP as first line treatment of uncomplicated malaria in 
Maputo Province, southern Mozambique. 
 MATERIALS AND METHODS 
 Study population and blood sample collection.  Finger-
prick blood from a random sample of children (2 to 15 years 
of age) were collected during annual cross-sectional surveys 
of asexual parasite prevalence in 26 sentinel sites in Maputo 
Province, Mozambique ( Figure 1 ) from 2004 to 2008. 15, 21 Areas 
within each district were identified as sentinel sites based 
on population size, geographical structure, and proximity 
to health facilities. Blood samples were collected on filter 
paper strips (Whatman filter paper no 1; Merck Laboratory 
Suppliers (Pty) Ltd., Durban, South Africa) from 120 children 
per sentinel site. The air dried filter paper blood spots were 
stored individually in zip-lock bags containing desiccant at 
room temperature until assayed. 
 Sample preparation and analysis.  Parasite DNA, from filter 
paper blood samples of rapid test (ICT; Global Diagnostics, 
Cape Town, South Africa) positive individuals, was extracted 
using the Chelex method. 22 Once a sample was confirmed as 
 P. falciparum positive by nested PCR, 23 it was subjected to  dhfr 
(codons 51, 59, 108, and 164) and  dhps (codons 436, 437, 540, 
and 518) mutational analysis. 24 Digestion products separated 
on a 2% agarose gel using electrophoresis were visualized 
and photographed using the MiniBIS documentation system 
(BioSystematica, Ceredigion Wales, UK). Codons were 
classified as either pure wild type, pure mutant, or mixed (both 
wild type and mutant haplotypes present in an individual 
sample). All genotyping analyses were run in duplicate with 
a third trial conducted on discordant results. When calculating 
overall prevalence of  P. falciparum isolates with mutant 
codons, codons with mixed genotypes were analyzed together 
with pure mutant codons. 
 Statistical analysis.  Statistical analysis was performed using 
Stata 10 (Stata Corp., College Station, TX). The prevalence of 
 dhfr and  dhps mutations were calculated for individual years 
and odds ratios (ORs), relative to 2004, and the association 
between “quintuple” mutation prevalence and prospectively 
defined explanatory variables (time since the introduction of 
AS-SP, time since deployment of SP-IPTp, age, and parasite 
prevalence) was assessed using a multilevel mixed effects 
logistic regression model. 25 Spearman’s correlation coefficients 
 Figure 1.  Sentinel sites and AS-SP implementation date in Maputo Province, Mozambique. 
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were used to quantify the level of association between year 
and these more biologically plausible explanatory variables. 
“Quintuple mutation” prevalence and parasite prevalence 
were assumed constant within each site for each study year. 
Sentinel sites were nested within districts, within which time 
since AS-SP and SP-IPT deployment remained constant. 
Within site and within district correlations of responses, and 
the number of children surveyed, were taken into account in 
the estimation of 95% confidence intervals (CIs). 
 Ethical considerations.  Ethics approval for this study was 
obtained from the South African Medical Research Council 
and the Ministry of Health in Mozambique. Blood samples 
were only taken if full informed consent from a parent/
guardian had been obtained. Children testing positive 
for malaria were referred to the closest health facility for 
appropriate treatment. 
 RESULTS 
 A total of 15,758 samples were collected over the 5-year 
study period, of which 2,361 (15.0%) were rapid test positive 
for  P. falciparum . DNA could be extracted from 2,329 (98.6%) 
rapid test positive samples of which 2,012 (86.4%) were con-
firmed as  P. falciparum positive by PCR. This discrepancy 
could partially be explained by the rapid test detection of the 
histidine-rich protein 2 malaria antigens in children in whom 
all parasites had been cleared 2 to 4 weeks previously. 26 Mean 
asexual parasite prevalence, based on PCR results, decreased 
from 44.2% in 2004 to 3.8% in 2008 (rate ratio [RR] 0.09; 
95% CI: 0.07–0.11;  P < 0.0001,  Table 1 ). Mixed genotypes were 
detected in 1030 (51%) samples. 
 No mutant alleles were detected in any of the samples tested 
at  dhfr codon 164 and  dhps codon 581. The  dhps 436 mutation 
was rare, with a prevalence of 0.003%. 
 Before the introduction of AS-SP,  dhfr triple mutation 
prevalence in Maputo Province was at 91.7%, increasing to 
96.3% by 2005, and remaining close to fixation (> 98%) for the 
remainder of the study period ( Figure 2A ). 
 Prevalence of the  dhps double was below 20% throughout 
all districts in Maputo Province before the introduction of 
AS-SP, with a mean prevalence of 11% ( Figure 2B ). However, 
as AS-SP implementation progressed through Maputo 
Province, the  dhps double mutation prevalence began increas-
ing, reaching high levels (64.5%) in 2007, a year after AS-SP 
and IPT with SP monotherapy had been deployed nationally 
(OR = 21.3; 95% CI: 12.6–36.3;  P < 0.0001,  Figure 2B ). This 
increase in prevalence continued, reaching 75.0% by 2008 
(OR = 40.4; 95% CI: 20.4–80.3;  P < 0.0001,  Figure 2B ). 
 Because the  dhfr triple mutation was already at fixation 
in 2004, the prevalence of parasites carrying the “quintu-
ple” mutation tracked the  dhps double mutation prevalence. 
“Quintuple” mutation prevalence had increased markedly by 
2006 (OR = 9.4; 95% CI: 6.9–13.0;  P < 0.0001) and continued 
to increase in 2007 (OR = 22.1; 95% CI: 13.0–37.6;  P < 0.0001), 
reaching 75.0% by 2008 (OR = 42.2; 95% CI: 21.3–83.7;  P < 
0.0001;  Figure 2C ). 
 Univariate and multiple logistic regression analysis were 
used to explore whether prospectively defined variables could 
explain the observed increase in “quintuple” mutation preva-
lence over time ( Table 2 ). Univariate analysis showed a posi-
tive relationship between “quintuple” mutation prevalence 
and months since artesunate plus SP deployment (OR = 1.11; 
95% CI: 1.10–1.12;  P < 0.0001), years since deployment of SP 
IPTp policy (OR = 4.40; 95% CI: 3.43–5.65;  P < 0.0001), and 
fever (OR = 2.26; 95% CI: 1.32–3.87;  P = 0.003). There was 
a negative association with sentinel site parasite prevalence 
(OR = 0.95; 95% CI: 0.94–0.95;  P < 0.0001) and with age (OR = 
0.95; 95% CI: 0.93–0.98;  P = 0.003). There was strong co-
linearity between calendar year and duration of AS-SP use 
( R = 0.83); a weak negative correlation with parasite preva-
lence ( R = 0.49) but none with age ( R = 0.04) ( Figure 3 ). As 
SP-IPTp was implemented nationally (and thus in all study 
sites) in mid 2006 there was perfect correlation of this explan-
atory variable with the year after 2005. Probably as a result 
of these correlations with time, only age and fever remained 
significantly associated with “quintuple” mutation prevalence 
after adjusting for confounding with study year ( Table 2 ). No 
association between “quintuple” mutation prevalence and 
gender ( P = 0.31) was found. 
 DISCUSSION 
 We report the first data documenting the routine surveil-
lance of temporal changes in resistance after large-scale sys-
tematic deployment of an ACT in Africa. Following the 
phased deployment of AS-SP in Maputo Province, southern 
Mozambique,  dhfr triple mutation prevalence remained at 
fixation. More importantly, the prevalence of parasites with 
the  dhps double, associated with sulfadoxine resistance, and 
“quintuple” mutations, associated with SP treatment failure, 
increased rapidly, both reaching an overall prevalence of 75% 
by 2008. Our findings suggest that the systematic, large-scale 
deployment of artesunate plus SP, as first line treatment of 
uncomplicated malaria since 2004, has not delayed the spread 
of SP resistance markers and may be contributing to the selec-
tion of parasites carrying these resistance markers. 
 These findings contrast sharply with the observed decrease 
in mefloquine resistance after the systematic deployment of 
the artesunate-mefloquine combination on the north-west bor-
der of Thailand, 27, 28 although falciparum malaria transmission 
 Table 1 
 Parasite prevalence (%) based on polymerase chain reaction (PCR) results by district and year 
District 2004 2005 2006 2007 2008
Namaacha 4.6% (11/239) 3.9% (10/256) 3.8% (10/263) 1.7% (2/118) 1.0% (2/200)
Matutuine 8.5% (45/529) 6.3% (18/286) 3.3% (19/576) 2.4% (9/375) 1.5% (7/467)
Boane 28.0% (87/311) 15.3% (46/301) 12.8% (58/453) 1.4% (4/286) 4.0% (14/350)
Marracuene 29.5% (115/390) 34.4% (97/282) 21.4% (68/318) 4.0% (12/300) 2.9% (10/345)
Magude 62.0% (337/544) 40.7% (190/467) 24.2% (123/508) 11.1% (54/486) 5.2% (18/346)
Moamba 42.5% (16 /393) 18.3% (81/443) 19.3% (59/306) 6.2% (9/145) 2.1% (9/429)
Matola 36.8% (79/215) 47.9% (104/217) 34.8% (71/204) 37.1% (51/137) 5.1% (16/314)
Total 44.2% (841/1903) 33.7% (546/1620) 21.8% (408/1872) 18.6% (141/758) 3.8% (76/2000)
791ACTS AND SP MUTATIONS
reduced significantly over the study periods in both loca-
tions. 15, 27 Both mefloquine and SP have a long elimination 
half-life, which provides a selective filter for resistant parasites 
acquired elsewhere. 29– 32 A plausible explanation for these con-
trasting results is that on the north-west border of Thailand 
there is minimal local transmission, with most malarial infec-
tions originating in neighboring Burma, where the limited avail-
ability of mefloquine has resulted in most falciparum isolates 
 Table 2 
 Factors associated with “quintuple” mutation prevalence in Maputo Province between 2004 and 2008 (within district and site correlations are taken 
into account in the estimation of confidence intervals) 
 Unadjusted OR 95% CI *  P value Adjusted OR 95% CI *  P value
2004 1.0 – – 1.0 – –
2005 1.56 1.12–2.18 0.009 1.50 1.05–2.14 0.026
2006 9.44 6.86–13.00 < 0.0001 9.30 5.48–15.80 < 0.0001
2007 22.14 13.03–37.60 < 0.0001 21.47 8.48–54.34 < 0.0001
2008 42.24 21.32–83.67 < 0.0001 37.04 9.45–145.19 < 0.0001
Duration AS-SP use (months) 1.11 1.10–1.12 < 0.0001 0.99 0.95–1.02 0.416
Duration SP-IPTp use (years) 4.40 3.43–5.65 < 0.0001  †  †  † 
Age (years) 0.95 0.93–0.99 0.003 0.92 0.89–0.96 < 0.0001
Parasite prevalence (%) 0.95 0.94–0.95 < 0.0001 0.99 0.98–1.00 0.290
Gender 0.90 0.74–1.11 0.311 0.84 0.66–1.07 0.152
Fever 2.26 1.32–3.87 0.003 2.35 1.29–4.29 0.005
 * Within site and within district correlations of mutation frequency were taken into account in the estimation of 95% confidence intervals (CI). 
 † The adjusted odds ratio (OR) for the effect of intermittent preventive treatment in pregnancy (IPTp) could not be evaluated because of perfect correlation with the year after 2005. 
 Figure 2.  Prevalence of the ( A )  dhfr triple mutation, ( B )  dhps double mutation, and ( C ) “quintuple” mutation by district and year in Maputo 
Province, Mozambique. 
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being mefloquine sensitive. This is not the case in Mozambique 
where most neighboring countries show a high prevalence of 
parasites carrying the  dhfr and  dhps mutations. 11– 13, 21 
 There are a number of local factors other than the region 
wide increase in  dhfr and  dhps mutations that may have con-
tributed to the alarmingly rapid spread of SP-resistant par-
asites in Maputo Province after the systematic large-scale 
deployment of AS-SP. These include the fixation of the  dhfr 
triple mutation before the commencement of AS-SP deploy-
ment in 2004, 21 and the use of SP monotherapy for IPT of 
pregnant women since 2006. People with resistant parasites 
tend to have enhanced gametocyte carriage and are more 
infectious to mosquitoes than individuals with wild parasites, 
even during the primary infection. 33, 34 Although gametocyte 
carriage is substantially reduced after the addition of AS to 
SP, 35 gametocyte transmission to mosquitoes is not completely 
halted 36 and data are needed to determine whether this ACT 
alters the ratio of resistant to sensitive infections seen after SP 
monotherapy. 
 In addition to the factors listed previously that could have 
contributed to the rapid selection and spread of SP-resistant 
falciparum parasites in southern Mozambique, pharmacoki-
netic studies have shown that children less than 5 years of age 
have been systematically under-dosed with the currently rec-
ommended SP dose. 37 Sub-therapeutic drug concentrations 
together with lack of acquired immunity could explain the sig-
nificantly increased risk of mutations found in parasites infect-
ing young children in Maputo Province. 16 
 For the benefits of ACTs to be realized, it is essential that 
the individual component drugs are effective in their own 
right. This is most critical now that artemisinin resistance has 
been confirmed in South East Asia 38, 39 In infections with con-
comitant resistance to the longer-acting partner drug, ACTs 
provide selective pressure for artemisinin resistance. It is 
imperative that resistance in partner drugs is closely moni-
tored, to ensure that national treatment policies remain effec-
tive. This is of particular importance in countries where malaria 
control interventions have been successful, markedly reducing 
malaria incidence and thereby limiting the feasibility of  in vivo 
therapeutic efficacy studies. 
 Although the negative association between parasite prev-
alence and “quintuple” mutation prevalence was not con-
firmed in our multivariable analysis, the primary sources of 
antimalarial drug resistance historically have been low inten-
sity transmission areas. Because of the lack of immunity in 
these populations, most infections are symptomatic, resulting 
in increased treatment seeking behavior and drug pressure. 
This is becoming increasingly pertinent in Africa in light of the 
recent successes in drastically reducing the malaria burden in 
countries with previously high transmission intensities, includ-
ing Kenya, Rwanda, Tanzania, Zanzibar, The Gambia, Eritrea, 
Equatorial Guinea, and southern Mozambique. 40 
 The role of SP monotherapy for IPT may need to be recon-
sidered in light of our data showing that the “quintuple” 
mutation is nearing fixation in southern Mozambique, and the 
potential contribution of SP-IPTp to the spread of SP resis-
tance. 14 Although a relationship between SP resistance and 
the benefits provided by SP-IPTp must exist, the SP resistance 
threshold at which IPTp ceases to be effective has not yet been 
determined. 41 
 African countries with high pre-existing levels of SP resis-
tance have achieved poor cure rates using AS-SP. 42, 43 Although 
AS-SP was shown to be highly efficacious at the start of ACT 
roll out, 16 the high pre-existing  dhfr triple mutation prevalence 
at the time of AS-SP implementation, together with the rather 
sharp increase in both the  dhps double and “quintuple” muta-
tions following ACT implementation, is cause for concern. 
Allen and colleagues 16 showed the presence of the “quintuple” 
mutation resulted in a 3-fold increased risk of treatment fail-
ure in Maputo Province, after adjusting for treatment arm, age, 
and temperature. Despite the marked increase in the “quin-
tuple” mutation over the study period, the  dhfr 164 mutation, 
 Figure 3.  Correlation between study year and ( A ) duration of 
AS-SP use ( R = 0.84), ( B ) parasite prevalence ( R = −0.49), and ( C ) 
age ( R = 0.04). 
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associated with highly pyrimethamine-resistant parasites was 
not detected. 
 The dramatic reduction in asexual parasite prevalence in 
Maputo Province can be attributed to a combination of inten-
sive indoor residual spraying 15 and effective case management 
following the AS-SP deployment. For this impressive malaria 
control program to be sustained it is essential that effective 
insecticides and antimalarials continue to be used. The steep 
rise in “quintuple” mutations found in this study points to a 
reduced useful therapeutic lifespan of AS-SP. The low asex-
ual parasite prevalence and high “quintuple” mutation preva-
lence found in our study, combined with the ongoing use of SP 
monotherapy for IPTp, could provide favorable conditions for 
artesunate resistance emergence. Additional concerns were 
that SP dosing is probably sub-optimal in young children and 
that AS-SP could not be provided as a fixed dose combination. 
On these grounds a change in antimalarial treatment policy 
to artemether-lumefantrine is currently being implemented by 
the Mozambican Ministry of Health. 
 Received July 15, 2009. Accepted for publication February 6, 2010. 
 Note: Supplemental appendix appears online at  www.ajtmh.org . 
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